B cell-directed therapies in multiple sclerosis

Neurodegenerative Disease Management
Christiane GasperiBernhard Hemmer

Abstract

Multiple sclerosis (MS) is a chronic inflammatory neurological disease of the CNS that goes along with demyelination and neurodegeneration. It is probably caused by an autoimmune response against the CNS, which emerges from the interplay of genetic and environmental factors. Although major progress has been made in the treatment of MS, it is still the leading cause for acquired nontraumatic neurological disability in young adults. Several therapeutic agents have been approved for the treatment of relapsing-remitting MS (RRMS), aiming at the reduction of relapses and a delay in disability progression. Three therapeutic monoclonal antibodies targeting CD20-positive B cells (rituximab, ocrelizumab and ofatumumab) were investigated in MRI-based Phase II and Phase III trials in RRMS, providing consistent evidence for a disease-ameliorating effect of B cell depleting therapies in MS. Here, we discuss the role of B cells and review current and future therapeutic approaches to target B cells in MS.

References

Oct 1, 1988·Journal of Neurology, Neurosurgery, and Psychiatry·A Compston
Sep 1, 1994·Immunology Today·T F Tedder, P Engel
Sep 28, 2000·The New England Journal of Medicine·J H NoseworthyB G Weinshenker
Aug 16, 2003·The Journal of Biological Chemistry·Haidong LiJulie P Deans
Aug 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gregory P OwensDonald H Gilden
Oct 3, 2003·Nature Reviews. Immunology·Eric J Kunkel, Eugene C Butcher
Apr 1, 2005·Brain : a Journal of Neurology·Sabine CepokBernhard Hemmer
May 4, 2005·Trends in Immunology·Antonio UccelliVito Pistoia
Apr 1, 2006·Cellular Immunology·Daniel Rodríguez-Pinto
Oct 4, 2006·Neuron·Stephen L Hauser, Jorge R Oksenberg
Feb 15, 2008·The New England Journal of Medicine·Stephen L HauserUNKNOWN HERMES Trial Group
Jun 19, 2008·Annual Review of Neuroscience·Bruce D Trapp, Klaus-Armin Nave
Sep 25, 2008·Nature Clinical Practice. Neurology·Marinos C Dalakas
Oct 31, 2008·Lancet·Alastair Compston, Alasdair Coles
Apr 3, 2009·Brain : a Journal of Neurology·Josa M FrischerHans Lassmann
Oct 3, 2009·Nature Reviews. Rheumatology·Thomas F Tedder
Dec 10, 2009·Neurology·Marcus KochHelen Tremlett
Dec 30, 2009·The Journal of Clinical Investigation·Taco W KuijpersRené A W van Lier
Jan 30, 2010·The Journal of Rheumatology·Ronald F van VollenhovenRavi Rao
Jul 8, 2010·The Journal of Pharmacology and Experimental Therapeutics·Ronald HerbstAnthony J Coyle
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck MorschhauserDavid M Goldenberg
Dec 24, 2010·Therapeutic Advances in Neurological Disorders·Hans-Peter Hartung, Bernd C Kieseier
Mar 5, 2011·British Journal of Pharmacology·Cris S ConstantinescuBruno Gran
May 11, 2011·Archives of Neurology·David B CliffordKenneth L Tyler
Oct 13, 2012·Journal of Hematology & Oncology·Shundong CangDelong Liu
Nov 20, 2012·The Journal of Clinical Investigation·H-Christian von BüdingenStephen L Hauser
Apr 10, 2013·Arthritis Research & Therapy·Stephan BlümlRonald Herbst

❮ Previous
Next ❯

Citations

Mar 13, 2016·Autoimmunity Reviews·Ron Milo
May 29, 2016·Journal of Neuroimmunology·Qingrong HuangJuhua Zhou
Jan 28, 2017·Neurodegenerative Disease Management·Laura Dormer
Mar 21, 2017·British Journal of Pharmacology·Ai-Lan NguyenJudith Field
Oct 27, 2017·Acta Neurologica Scandinavica·P Sundström
Apr 28, 2019·Expert Opinion on Biological Therapy·Mihai AncauBernhard Hemmer
Oct 31, 2017·Neurology. Neuroimmunology and Neuroinflammation·Divyanshu DubeyOlaf Stüve
May 22, 2018·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Patricia LechnerGabriele Multhoff
Mar 8, 2017·European Journal of Clinical Pharmacology·Sun Ku LeeMiroslawa Nowak
Feb 23, 2017·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Ece ErdağFeyza Arıcıoğlu
May 19, 2018·Therapeutic Advances in Neurological Disorders·Patricia MuleroXavier Montalban
Jul 4, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Maria Pia AmatoUNKNOWN 2016 ECTRIMS Focused Workshop Group
Apr 30, 2017·Therapeutic Advances in Neurological Disorders·Stefan BittnerSven G Meuth
Jul 9, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Michelle L JamesSanjiv S Gambhir

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01194570
NCT01412333
NCT01247324
NCT01457924
NCT01585766
NCT02200770
NCT02038049

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Autoimmune Disease Therapy

In autoimmune diseases, the immune system responds and attacks self-antigens and damages or impairs the function of the tissues. The treatment for autoimmune diseases often involves immunosuppressive agents, but newer treatments are being investigated. Discover the latest research on autoimmune disease therapy here.